Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

Claims on social media suggest Pfizer's COVID vaccine has fatal side effects, referencing a US House document. However, the ...

Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...